Efinaconazole
CAS: 164650-44-6
Ref. 3D-FD58714
1g | 454,00 € | ||
2g | 717,00 € | ||
100mg | 156,00 € | ||
250mg | 218,00 € | ||
500mg | 322,00 € |
Información del producto
- (αR,βR)-α-(2,4-Difluorophenyl)-β-methyl-4-methylene-α-(1H-1,2,4-triazol-1-ylmethyl)-1-piperidineethanol
- (2R,3R)-2-(2,4-Difluorophenyl)-3-(4-methylenepiperidin-1-yl)-1-(4H-1,3,4-triazol-4-yl)butan-2-ol
- (R,R)-2-(2,4-Difluorophenyl)-3-(4-methylenepiperidin-1-yl)-1-(1,2,4-triazol-1-yl)-2-butanol
- 1-Piperidineethanol, α-(2,4-difluorophenyl)-β-methyl-4-methylene-α-(1H-1,2,4-triazol-1-ylmethyl)-, (αR,βR)-
- 1-Piperidineethanol, α-(2,4-difluorophenyl)-β-methyl-4-methylene-α-(1H-1,2,4-triazol-1-ylmethyl)-, [R-(R*,R*)]-
- Jublia
- KP 103 (pharmaceutical)
- Kp-103
Efinaconazole is a synthetic antifungal agent that is active against dermatophytes, yeasts and molds. It is a new generation triazole with potent in vitro antifungal activity and long-term efficacy. Efinaconazole has been shown to be effective against Candida albicans, Candida dubliniensis, Candida glabrata, Candida parapsilosis, Candida tropicalis, and Trichophyton mentagrophytes. The pharmacokinetic properties of efinaconazole have been studied using LC-MS/MS method. These results showed that the drug is well absorbed after oral administration and has a half-life of about 2 hours. In addition, this drug does not show any significant interactions with other drugs or food products. Efinaconazole can be used for the treatment of skin lesions caused by candidiasis or tinea corporis.
Propiedades químicas
Consulta técnica sobre: 3D-FD58714 Efinaconazole
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.